# Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia

> **NCT04862962** · — · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 120 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose

## Key facts

- **NCT ID:** NCT04862962
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2022-01-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862962, "Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04862962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*